Annual SGA
$146.09 M
+$8.35 M+6.06%
December 31, 2023
Summary
- As of February 7, 2025, XERS annual SGA is $146.09 million, with the most recent change of +$8.35 million (+6.06%) on December 31, 2023.
- During the last 3 years, XERS annual SGA has risen by +$72.36 million (+98.14%).
- XERS annual SGA is now at all-time high.
Performance
XERS SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$44.97 M
+$4.98 M+12.44%
September 30, 2024
Summary
- As of February 7, 2025, XERS quarterly SGA is $44.97 million, with the most recent change of +$4.98 million (+12.44%) on September 30, 2024.
- Over the past year, XERS quarterly SGA has increased by +$7.68 million (+20.60%).
- XERS quarterly SGA is now -17.00% below its all-time high of $54.18 million, reached on December 31, 2021.
Performance
XERS Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$2.57 B
-$63.11 M-2.52%
September 30, 2024
Summary
- As of February 7, 2025, XERS TTM SGA is -$2.57 billion, with the most recent change of -$63.11 million (-2.52%) on September 30, 2024.
- Over the past year, XERS TTM SGA has dropped by -$2.71 billion (-1899.21%).
- XERS TTM SGA is now -4143.27% below its all-time high of -$60.59 million.
Performance
XERS TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
XERS Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.1% | +20.6% | -1899.2% |
| 3 y3 years | +98.1% | +20.6% | -1899.2% |
| 5 y5 years | +592.0% | +20.6% | -1899.2% |
XERS Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +16.2% | -17.0% | +36.3% | -59.8% | at low |
| 5 y | 5-year | at high | +131.7% | -17.0% | +172.8% | -227.2% | at low |
| alltime | all time | at high | +3498.4% | -17.0% | +3253.4% | -4143.3% | at low |
Xeris Biopharma Holdings Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $44.97 M(+12.4%) | $160.91 M(+5.0%) |
| Jun 2024 | - | $39.99 M(+4.2%) | $153.23 M(+1.6%) |
| Mar 2024 | - | $38.38 M(+2.2%) | $150.87 M(+3.3%) |
| Dec 2023 | $146.09 M(+6.1%) | $37.57 M(+0.8%) | $146.09 M(+2.2%) |
| Sep 2023 | - | $37.29 M(-0.9%) | $142.88 M(+2.0%) |
| Jun 2023 | - | $37.63 M(+12.0%) | $140.09 M(+3.4%) |
| Mar 2023 | - | $33.60 M(-2.2%) | $135.44 M(-1.7%) |
| Dec 2022 | $137.75 M(+9.6%) | $34.36 M(-0.4%) | $137.75 M(-12.6%) |
| Sep 2022 | - | $34.49 M(+4.6%) | $157.57 M(+5.3%) |
| Jun 2022 | - | $32.98 M(-8.2%) | $149.61 M(+5.0%) |
| Mar 2022 | - | $35.91 M(-33.7%) | $142.55 M(+13.4%) |
| Dec 2021 | $125.72 M(+70.5%) | $54.18 M(+104.2%) | $125.72 M(+40.4%) |
| Sep 2021 | - | $26.54 M(+2.3%) | $89.54 M(+12.6%) |
| Jun 2021 | - | $25.93 M(+35.9%) | $79.49 M(+11.6%) |
| Mar 2021 | - | $19.08 M(+6.0%) | $71.20 M(-3.4%) |
| Dec 2020 | $73.73 M | $18.00 M(+9.2%) | $73.73 M(-3.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $16.48 M(-6.6%) | $76.38 M(+2.1%) |
| Jun 2020 | - | $17.64 M(-18.3%) | $74.77 M(+3.6%) |
| Mar 2020 | - | $21.61 M(+4.7%) | $72.15 M(+14.4%) |
| Dec 2019 | $63.06 M(+198.7%) | $20.64 M(+38.8%) | $63.06 M(+23.3%) |
| Sep 2019 | - | $14.88 M(-1.0%) | $51.14 M(+25.0%) |
| Jun 2019 | - | $15.02 M(+20.0%) | $40.92 M(+34.6%) |
| Mar 2019 | - | $12.52 M(+43.5%) | $30.39 M(+43.9%) |
| Dec 2018 | $21.11 M(+163.4%) | $8.72 M(+87.6%) | $21.11 M(+36.3%) |
| Sep 2018 | - | $4.65 M(+3.4%) | $15.49 M(+20.5%) |
| Jun 2018 | - | $4.50 M(+38.9%) | $12.85 M(+29.7%) |
| Mar 2018 | - | $3.24 M(+4.6%) | $9.91 M(+23.7%) |
| Dec 2017 | $8.02 M(+97.4%) | $3.10 M(+53.6%) | $8.02 M(+63.0%) |
| Sep 2017 | - | $2.02 M(+29.4%) | $4.92 M(+69.6%) |
| Jun 2017 | - | $1.56 M(+16.3%) | $2.90 M(+116.3%) |
| Mar 2017 | - | $1.34 M | $1.34 M |
| Dec 2016 | $4.06 M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual SGA?
- What is the all time high annual SGA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual SGA year-on-year change?
- What is Xeris Biopharma Holdings quarterly SGA?
- What is the all time high quarterly SGA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly SGA year-on-year change?
- What is Xeris Biopharma Holdings TTM SGA?
- What is the all time high TTM SGA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM SGA year-on-year change?
What is Xeris Biopharma Holdings annual SGA?
The current annual SGA of XERS is $146.09 M
What is the all time high annual SGA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual SGA is $146.09 M
What is Xeris Biopharma Holdings annual SGA year-on-year change?
Over the past year, XERS annual SGA has changed by +$8.35 M (+6.06%)
What is Xeris Biopharma Holdings quarterly SGA?
The current quarterly SGA of XERS is $44.97 M
What is the all time high quarterly SGA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly SGA is $54.18 M
What is Xeris Biopharma Holdings quarterly SGA year-on-year change?
Over the past year, XERS quarterly SGA has changed by +$7.68 M (+20.60%)
What is Xeris Biopharma Holdings TTM SGA?
The current TTM SGA of XERS is -$2.57 B
What is the all time high TTM SGA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM SGA is -$60.59 M
What is Xeris Biopharma Holdings TTM SGA year-on-year change?
Over the past year, XERS TTM SGA has changed by -$2.71 B (-1899.21%)